Bio-Path Holdings (BPTH) Misses Q4 EPS by 144c

Bio-Path Holdings (NASDAQ: BPTH) reported Q4 EPS of ($1.91), $1.44 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Bio-Path Holdings (BPTH) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• DeFi Technologies (DEFT) PT Lowered to $1 at Benchmark Following Q2 Miss
• GLJ Research on Sell Rated Tesla (TSLA): 'We now see FSD as the main reason TSLA’s stock will bleed lower this year'